About BAGIM

BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.

Tuesday, November 12, 2019

BAGIM Event: Rebecca Swett

Please join us as we hear an amazing talk by Rebecca Swett entitled "Effective Simulations, Effective Team."

This event will be held on Thursday, November 21st at 6:00pm at Novartis.

Dr. Swett graduated from Wayne State University in Detroit, where she applied molecular dynamics to the development and optimization of covalent inhibitors of the Clostridium Difficile toxins, and developed methods to apply interference in protein-protein recognition as a mechanism of inhibition, leading to her first patent. Additionally, she developed software connect genotypes to phenotypes by gene region of interest, in a hypothesis-driven manner and validated the results with simulations and in vitro experiments. She then completed a postdoc at Novartis with an academic mentor at Stanford. Here, she worked on applying ultra-fine print molecular dynamics to the use of solvation in lead optimization, application of Markov State Modeling to the identification of targetable metastable protein states for the development of flu treatments, and developed predictive models to discriminate between ligand effects on correlated protein motions in high throughput MD. She currently is at Vertex Pharmaceuticals where she uses an array of ligand and structure based methods, as well as predictive modeling and molecular dynamics, to pursue treatments for Cystic Fibrosis and other targets